Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Myriad Genetics, Inc. (MYGN) had Debt to Capital Ratio of 0.26 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$200.40M |
|
$-34.10M |
|
$62.80M |
|
$137.60M |
|
$231.10M |
|
$-30.70M |
|
$-3.40M |
|
$-34.10M |
|
$-34.10M |
|
$-34.10M |
|
$-34.10M |
|
$-34.10M |
|
$-34.10M |
|
$-30.70M |
|
$-12.80M |
|
93.70M |
|
93.70M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$312.80M |
|
$111.50M |
|
$360.90M |
|
$673.70M |
|
$130.20M |
|
$120.30M |
|
$206.10M |
|
$336.30M |
|
$337.40M |
|
$144.60M |
|
$337.40M |
|
94.40M |
|
| Cash Flow Statement Financials | |
$-15.70M |
|
$-6.50M |
|
$-3.00M |
|
$151.30M |
|
$126.00M |
|
$-25.30M |
|
$6.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.40 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.26 |
0.36 |
|
68.66% |
|
-15.32% |
|
-15.32% |
|
-- |
|
-17.02% |
|
-17.02% |
|
$-21.10M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
2.25 |
|
1.62 |
|
55.60 |
|
-10.11% |
|
-23.58% |
|
-5.06% |
|
-7.45% |
|
$3.57 |
|
$-0.23 |
|
$-0.17 |
|